• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

内源性受体结合型尿激酶介导人肺癌细胞系A549和Calu-1的组织侵袭。

Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell lines A549 and Calu-1.

作者信息

Bruckner A, Filderman A E, Kirchheimer J C, Binder B R, Remold H G

机构信息

Department of Rheumatology and Immunology, Brigham and Women's Hospital, Boston, Massachusetts 02115.

出版信息

Cancer Res. 1992 Jun 1;52(11):3043-7.

PMID:1375533
Abstract

Macrophage colony-stimulating factor (CSF-1) increases the tissue invasive potential of the CSF-1 receptor-bearing lung carcinoma cell lines A549 and Calu-1 by increasing the number of endogenously bound urokinase-type plasminogen activators (u-PA)s on these cells. CSF-1, at concentrations which optimize invasion of A549 and Calu-1 cells into human amnion membranes (250 ng/ml), maximally augments the number of u-PA receptors occupied by endogenously produced urokinase. Preincubation of A549 and Calu-1 cells with the anti-u-PA monoclonal antibody MPW5UK (25 micrograms/ml) or with a 20- to 40-fold stoichiometric excess of fluid phase type 2 plasminogen activator inhibitor abrogates invasiveness, indicating that functionally active cell surface u-PA is essential for tissue invasion. In contrast, fluid phase type 1 plasminogen activator inhibitor (PAI-1, 5-15 units/ml) does not inhibit invasiveness unless preincubated with the amnion membranes. Inhibition of invasion by PAI-1 is abolished by presaturating the amnion membranes with antiitronectin monoclonal antibody (10 micrograms/ml) which prevents binding of PAI-1 to tissue-associated vitronectin. Binding of PAI-1 to tissue vitronectin is therefore a prerequisite for its inhibitory action. Thus, endogenously receptor-bound u-PA is the primary protease mediating CSF-1-induced tissue invasiveness of the lung carcinoma cell lines A549 and Calu-1.

摘要

巨噬细胞集落刺激因子(CSF-1)通过增加A549和Calu-1这两种携带CSF-1受体的肺癌细胞系内源性结合的尿激酶型纤溶酶原激活剂(u-PA)的数量,提高其组织侵袭潜能。CSF-1在优化A549和Calu-1细胞向人羊膜侵袭的浓度(250 ng/ml)下,能最大程度地增加内源性产生的尿激酶所占据的u-PA受体数量。用抗u-PA单克隆抗体MPW5UK(25微克/毫升)或20至40倍化学计量过量的液相2型纤溶酶原激活剂抑制剂对A549和Calu-1细胞进行预孵育,可消除其侵袭性,这表明具有功能活性的细胞表面u-PA对组织侵袭至关重要。相比之下,液相1型纤溶酶原激活剂抑制剂(PAI-1,5 - 15单位/毫升)除非与羊膜预孵育,否则不会抑制侵袭性。用抗玻连蛋白单克隆抗体(10微克/毫升)使羊膜预饱和,可消除PAI-1对侵袭的抑制作用,因为该抗体可阻止PAI-1与组织相关玻连蛋白结合。因此,PAI-1与组织玻连蛋白的结合是其发挥抑制作用的前提条件。所以,内源性受体结合的u-PA是介导CSF-1诱导的A549和Calu-1肺癌细胞系组织侵袭性的主要蛋白酶。

相似文献

1
Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell lines A549 and Calu-1.内源性受体结合型尿激酶介导人肺癌细胞系A549和Calu-1的组织侵袭。
Cancer Res. 1992 Jun 1;52(11):3043-7.
2
Matrix-bound plasminogen activator inhibitor type 1 inhibits the invasion of human monocytes into interstitial tissue.基质结合的1型纤溶酶原激活物抑制剂可抑制人单核细胞向间质组织的浸润。
J Immunol. 1990 Sep 1;145(5):1518-22.
3
Endogenous receptor-bound urokinase mediates tissue invasion of human monocytes.内源性受体结合型尿激酶介导人单核细胞的组织侵袭。
J Immunol. 1989 Oct 15;143(8):2634-9.
4
Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation.纤溶酶原激活物抑制剂-1可独立于其作为纤溶酶原激活抑制剂的功能,抑制整合素和玻连蛋白介导的细胞迁移。
Exp Cell Res. 1997 May 1;232(2):420-9. doi: 10.1006/excr.1997.3540.
5
Macrophage colony-stimulating factor (CSF-1) enhances invasiveness in CSF-1 receptor-positive carcinoma cell lines.巨噬细胞集落刺激因子(CSF-1)增强CSF-1受体阳性癌细胞系的侵袭性。
Cancer Res. 1992 Jul 1;52(13):3661-6.
6
Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase.巨噬细胞集落刺激因子通过尿激酶介导卵巢癌细胞的侵袭。
Cancer Res. 1995 Apr 1;55(7):1578-85.
7
The urokinase receptor is a major vitronectin-binding protein on endothelial cells.尿激酶受体是内皮细胞上一种主要的玻连蛋白结合蛋白。
Exp Cell Res. 1996 May 1;224(2):344-53. doi: 10.1006/excr.1996.0144.
8
Influence of urokinase on cell proliferation and invasion.尿激酶对细胞增殖和侵袭的影响。
Blood Coagul Fibrinolysis. 1990 Dec;1(6):717-20.
9
Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer.
Cancer Res. 1991 Jul 15;51(14):3690-5.
10
The urokinase-type plasminogen activator, its receptor and u-PA inhibitor type-1 affect in vitro growth and invasion of Kaposi's sarcoma and capillary endothelial cells: role of HIV-Tat protein.尿激酶型纤溶酶原激活剂、其受体及1型尿激酶型纤溶酶原激活剂抑制剂对卡波西肉瘤和毛细血管内皮细胞体外生长及侵袭的影响:HIV-Tat蛋白的作用
Int J Oncol. 2005 Jul;27(1):223-35.

引用本文的文献

1
Role of CSF-1 in progression of epithelial ovarian cancer.CSF-1 在卵巢上皮性癌进展中的作用。
Future Oncol. 2009 Nov;5(9):1429-40. doi: 10.2217/fon.09.103.
2
Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.尿激酶型纤溶酶原激活物及其受体和纤溶酶原激活物抑制剂-2在食管鳞状细胞癌中的细胞分布及临床价值
Am J Pathol. 2000 Feb;156(2):567-75. doi: 10.1016/S0002-9440(10)64761-X.
3
Posttranscriptional regulation of urokinase receptor gene expression in human lung carcinoma and mesothelioma cells in vitro.人肺癌和间皮瘤细胞中尿激酶受体基因表达的转录后调控(体外研究)
Mol Cell Biochem. 1999 Sep;199(1-2):189-200. doi: 10.1023/a:1006914800447.
4
Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model.合成尿激酶抑制剂对小鼠乳腺肿瘤模型局部侵袭和转移的影响。
Breast Cancer Res Treat. 1996;40(3):209-23. doi: 10.1007/BF01806809.
5
Proteolysis and invasiveness of brain tumors: role of urokinase-type plasminogen activator receptor.脑肿瘤的蛋白水解作用与侵袭性:尿激酶型纤溶酶原激活物受体的作用
J Neurooncol. 1994;22(2):153-60. doi: 10.1007/BF01052890.
6
The pathophysiology and management of spine metastasis from lung cancer.肺癌脊柱转移的病理生理学与管理
J Neurooncol. 1995;23(2):109-20. doi: 10.1007/BF01053416.